Tenderwize
Zurück zur Suche

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 216 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Cinnarizin und Dimenhydrinat (ATC: N07CA22)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)
  • Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Vollständige Zusammenfassung anzeigen

This notice announces a non-exclusive discount agreement (Rabattvertrag) under §130a Abs. 8 SGB V for finished medicinal products containing the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22). It follows an open-house model, allowing any qualified pharmaceutical company to conclude a standard contract at any time. The contract runs for a maximum of 24 months from the earliest start date (01.06.2025) until 31.05.2027. The notice explicitly states it is not a public procurement under GWB but is published for transparency. No estimated value or framework maximum value is provided. The submission process is unclear: structured data indicates electronic submission is not allowed, but the XML notice mentions the possibility of submitting electronically signed documents via email.

Risiken

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Contract must be signed and returned to the contact address

Administrative

  • Must request and submit participation documents fully completed and signed

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

Non-exclusive discount agreements for finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22) under an open-house model. Any qualified pharmaceutical company can join at any time. No exclusivity. Contract duration: maximum 24 months, ending 31.05.2027 irrespective of start date. Early termination possible if the health insurance fund (AOK Sachsen-Anhalt) tenders exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline Mar 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
234181-2025

Dokumente (1)

Ähnliche Ausschreibungen